NYC - Prostate Cancer Research: Hope for the Future

NYC - Prostate Cancer Research: Hope for the Future
Date: 
Thu, 09/20/2012 - 6:30pm - 8:30pm
Prostate Cancer Research: Hope for the Future
 
Thursday, September 20
6:30 - 8:30 pm

Yale Club of New York City - Tap Room
50 Vanderbilt Ave

~~~~~~~

The Yale Club of New York City and the Association of Yale Alumni in Medicine invite you to hear the latest news on prostate cancer research from three research experts.

Dr. Peter Schulam, Chairman of the Yale School of Medicine Urology Department, will serve as lead panelist sharing news of the work at Yale. Dr. Avigdor Scherz is a Weizmann Institute of Science Professor who is conducting research on a novel therapeutic approach to treating prostate cancer, and Dr. Peter Scardino at Memorial Sloan-Kettering Cancer Center is collaborating with Dr. Scherz on the clinical applications of his research.

Please join the panelists in the Yale Club of New York City Tap Room for a reception at 6:30 pm and their discussion at 7:00 pm, followed by a Q & A. Reservations are required so please reserve your space at this free event by emailing events@yaleclubnyc.org by Monday, September 17.

~~~~~~~

YaleGALE, the Yale Global Alumni Leadership Exchange, is dedicated to strengthening higher education institutions around the world by exchanging best practices in alumni engagement. A number of volunteer leaders of Yale alumni organizations have been meeting over the past several years with their counterparts as well as administrative and faculty representatives from universities in Australia, Japan, Turkey, China, Israel and the United Kingdom. The Weismann Institute in Israel was one of the campuses visited this past February in an exchange with eight Israeli universities. Weismann has been in a collaborative relationship with Yale over the years, and the idea for a panel discussion arose when Professor Scherz's novel work on treating prostate cancer surfaced. Since Yale Medical School has had its own extensive research program underway in treating prostate cancer, and Sloan Kettering has been working on the clinical side of Professor Scherz's studies, we thought it would be wonderful to organize a panel covering these three initiatives.

""